HLB bioStep Co.,Ltd. (KOSDAQ:278650)

South Korea · Delayed Price · Currency is KRW

2,395.00

+155.00 (6.92%)

At close: Aug 11, 2026

-63.07% (1Y)

Market Cap	41.23B -62.4%
Revenue (ttm)	73.96B +22.9%
Net Income	-19.28B
EPS	-1,085.34
Shares Out	17.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,532
Open	2,260.00
Previous Close	2,240.00
Day's Range	2,200.00 - 2,395.00
52-Week Range	1,500.00 - 10,100.00
Beta	-0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About HLB bioStep

HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug development consulting and clinical trial services, and bioanalysis items. The company was formerly known as KNOTUS Co.,Ltd. HLB bioStep Co.,Ltd. was found... [Read more]

Industry Commercial Physical and Biological Research

Founded 2012

Employees 147

Stock Exchange KOSDAQ

Ticker Symbol 278650

Full Company Profile

Financial Performance

In 2025, HLB bioStep's revenue was 74.05 billion, an increase of 27.30% compared to the previous year's 58.17 billion. Losses were -18.96 billion, 121.4% more than in 2024.

Financial Statements